(Q38286376)

1 September 2017

1 reference

title

Immunotherapy and lung cancer: current developments and novel targeted therapies (English)

1 reference

1 September 2017

1 reference

1 reference

Duarte Domingues

1

1 reference

1 September 2017

Alice Turner

2

1 reference

1 September 2017

Maria Dília Silva

3

1 reference

1 September 2017

Dânia Sofia Marques

4

1 reference

1 September 2017

Juan Carlos Mellidez

5

1 reference

1 September 2017

Luciano Wannesson

6

1 reference

1 September 2017

Giannis Mountzios

7

1 reference

1 September 2017

Ramon Andrade de Mello

8

1 reference

1 September 2017

publication date

1 January 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

6

1 reference

1 September 2017

issue

11

1 reference

1 September 2017

page(s)

1221-1235

1 reference

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 September 2017

cites work

1 reference

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).

21 January 2018

1 reference

Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.

21 January 2018

1 reference

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer

21 January 2018

1 reference

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

Immunotherapy for lung cancer: ongoing clinical trials

21 January 2018

1 reference

Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer

21 January 2018

1 reference

Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy

21 January 2018

1 reference

Immunotherapy in lung cancer: "b7-bombers" and other new developments

21 January 2018

1 reference

How cigarette smoke skews immune responses to promote infection, lung disease and cancer

21 January 2018

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

Immunotherapy and the concept of a clinical cure

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

21 January 2018

1 reference

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

21 January 2018

1 reference

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients

21 January 2018

1 reference

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

21 January 2018

1 reference

Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.

21 January 2018

1 reference

Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models

21 January 2018

1 reference

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

Recent advances in immunotherapy for non-small-cell lung cancer

21 January 2018

1 reference

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models

21 January 2018

1 reference

Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors

21 January 2018

1 reference

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

21 January 2018

1 reference

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

21 January 2018

1 reference

Biomarkers and correlative endpoints for immunotherapy trials

21 January 2018

1 reference

Defining the critical hurdles in cancer immunotherapy

21 January 2018

1 reference

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

21 January 2018

1 reference

The VEGF family in cancer and antibody-based strategies for their inhibition

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.82

1 reference

1 September 2017

1 reference